Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.

Tadashi NamisakiKosuke KajiNaotaka ShimozatoDaisuke KayaTakahiro OzutsumiYuki TsujiYukihisa FujinagaKoh KitagawaMasanori FurukawaShinya SatoYasuhiko SawadaNorihisa NishimuraHiroaki TakayaYasushi OkuraKenichiro SekiHideto KawarataniKei MoriyaRyuichi NoguchiKiyoshi AsadaTakemi AkahaneAkira MitoroHitoshi Yoshiji

Published in: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2022)

OCA + losartan suppressed the ongoing hepatic fibrosis by attenuating gut barrier dysfunction and suppressing Ac-HSC proliferation. Combined therapy may be a promising novel approach for NASH with fibrosis.

Keyphrases

angiotensin ii
angiotensin converting enzyme
vascular smooth muscle cells
signaling pathway
liver fibrosis
oxidative stress
stem cells
mesenchymal stem cells
replacement therapy
smoking cessation